CLAIMS

1. Use of a population of allogeneic T cells for the manufacture of a medicament for the treatment of an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient, wherein the EBV-LPD is a disorder of cells of B cell lineage, wherein the human patient has failed (a) a combination chemotherapy to treat the EBV-LPD, (b) a therapy with an anti-CD20 monoclonal antibody to treat the EBV-LPD, and (c) a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells comprises EBV-specific T cells and is restricted by a human leukocyte antigen (HLA) allele shared with cells of the EBV-LPD.
2. The use of claim 1, wherein the EBV-LPD is resistant to the combination chemotherapy to treat the EBV-LPD.
3. The use of claim 1 or 2, wherein the human patient has failed multiple different combination chemotherapies to treat the EBV-LPD.
4. The use of claim 3, wherein the EBV-LPD is resistant to the multiple different combination chemotherapies to treat the EBV-LPD.
5. The use of any of claims 1-4, wherein the EBV-LPD is resistant to the radiation therapy to treat the EBV-LPD.
6. The use of any of claims 1-5, wherein the EBV-LPD is resistant to the therapy with the anti-CD20 monoclonal antibody to treat the EBV-LPD.
7. The use of any of claims 1-6, wherein the anti-CD20 monoclonal antibody is rituximab.
8. The use of any of claims 1-7, wherein the EBV-LPD is an EBV-positive lymphoma.
9. The use of any of claims 1-7, wherein the EBV-LPD is diffuse large B-cell lymphoma.
10. The use of any of claims 1-9, wherein the EBV-LPD is present in the central nervous system of the human patient.
11. The use of claim 10, wherein the EBV-LPD is present in the brain of the human patient.
12. The use of any of claims 1-11, wherein the human patient has been the recipient of a solid organ transplant from a transplant donor.
13. The use of any of claims 1-11, wherein the human patient has been the recipient of a hematopoietic stem cell transplant from a transplant donor.

14. The use of claim 12 or 13, wherein the population of allogeneic T cells is derived from a donor other than the transplant donor.
15. The use of any of claims 1-11, wherein the human patient is infected with HIV.
16. The use of any of claims 1-15, wherein the medicament is for administration to the human patient before administration to the human patient of a second population of allogeneic T cells comprising EBV-specific T cells; wherein the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD.